LLY

987.09

+0.77%↑

JNJ

223.39

-0.94%↓

ABBV

204.25

-1.41%↓

UNH

368.06

+1.2%↑

AZN

184.2

+1.77%↑

LLY

987.09

+0.77%↑

JNJ

223.39

-0.94%↓

ABBV

204.25

-1.41%↓

UNH

368.06

+1.2%↑

AZN

184.2

+1.77%↑

LLY

987.09

+0.77%↑

JNJ

223.39

-0.94%↓

ABBV

204.25

-1.41%↓

UNH

368.06

+1.2%↑

AZN

184.2

+1.77%↑

LLY

987.09

+0.77%↑

JNJ

223.39

-0.94%↓

ABBV

204.25

-1.41%↓

UNH

368.06

+1.2%↑

AZN

184.2

+1.77%↑

LLY

987.09

+0.77%↑

JNJ

223.39

-0.94%↓

ABBV

204.25

-1.41%↓

UNH

368.06

+1.2%↑

AZN

184.2

+1.77%↑

Home・Listă Acțiuni・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Deschisă

4.01 -4.07

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.88

Maxim

4.23

Indicatori cheie
By Trading Economics
Venit	-8.5M -35M
Angajați	106
EBITDA	-11M -37M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+106.25% upside

Dividende
By Dow Jones
Următoarele câștiguri	12 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	126M 290M
Deschiderea anterioară	8.08
Închiderea anterioară	4.01

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

1.23 / 1.45 Suport & Rezistență

Zentalis Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 mai 2026, 23:43 UTC

Evenimente importante

New Zealand's Unemployment Rate Falls in 1Q

5 mai 2026, 23:20 UTC

Acțiuni populare

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mai 2026, 21:48 UTC

Câștiguri

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mai 2026, 21:05 UTC

Achiziții, Fuziuni, Preluări

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mai 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mai 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mai 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5 mai 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mai 2026, 22:08 UTC

Câștiguri

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mai 2026, 22:07 UTC

Câștiguri

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:48 UTC

Câștiguri

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mai 2026, 21:48 UTC

Câștiguri

Pan American Silver 1Q Rev $1.2B >PAAS

5 mai 2026, 21:42 UTC

Câștiguri

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:38 UTC

Câștiguri

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:30 UTC

Câștiguri

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:29 UTC

Câștiguri

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:26 UTC

Câștiguri

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mai 2026, 21:25 UTC

Câștiguri

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mai 2026, 21:25 UTC

Câștiguri

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mai 2026, 21:24 UTC

Câștiguri

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:18 UTC

Câștiguri

Mistras Backs 2026 Rev $730M-$750M >MG

5 mai 2026, 21:17 UTC

Câștiguri

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mai 2026, 21:15 UTC

Câștiguri

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mai 2026, 21:12 UTC

Câștiguri

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mai 2026, 21:11 UTC

Câștiguri

SSR Mining 1Q Rev $581.8M >SSRM

5 mai 2026, 21:10 UTC

Câștiguri

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mai 2026, 21:10 UTC

Câștiguri

SSR Mining 1Q EPS $1.16 >SSRM

5 mai 2026, 21:08 UTC

Câștiguri

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:01 UTC

Câștiguri

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mai 2026, 21:01 UTC

Acțiuni populare

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparație

Modificare preț

Zentalis Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

106.25% sus

Prognoză pe 12 luni

Medie 8.25 USD 106.25%

Maxim 10 USD

Minim 4 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruZentalis Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Zentalis Pharmaceuticals Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

1.23 / 1.45Suport & Rezistență

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.